Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

[In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus


Speakers: Stacy Shord, FDA; Harald A.Weber, Seagen/Pfizer; Patrick Williams, Genentech; Donghua Yin, Pfizer; Peter C Trask, Genentech; Shelly Wang; Divya Samineni, Genentech
Organizers: Chunze Li, Jesse Yu, Joseph Chen (Department of Clinical Pharmacology, Genentech)
Date: 2024-04-26
Time: 8:45-17:00 Pacific Time
Registration fee: Regular attendees: $295; Academic/Students/Postdocs: $45; Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor: (2)Allucent; Olink Proteomics
Vendor show vendors registered to date: (2)BioAgilytix; Meadowhawk Biolabs
Registration: http://www.PBSS.org
Registration deadline:2024-04-25  (it will close sooner if the seating cap is reached)

About the Topic

Historically, dose selection in oncology was driven by the MTD paradigm. This traditional approach was partly driven by the few available therapies in oncology, and the need to bring effective drugs to the market as soon as possible. Now that the field of oncology drug development has matured and cancer patients are living longer than ever on chronic therapies, we as drug developers need to meet these new challenges by shifting our approach to oncology dose selection to a new paradigm. This one-day workshop will discuss the new regulatory expectations to oncology dose selection, various approaches to optimize oncology dose selection from a study design as well as statistical perspective, different clinical pharmacology considerations and related analysis to support dose selection, and evaluations using patient-reported outcomes. 


About the Speakers

Time (PST) 

Topic 

Presenter 

8:45 - 9:00 am 

PBSS Welcome and Introduction 

Shichang Miao (PBSS)

9:00 - 9:30 am 

FDA Embracing Innovation for Dosage Optimization of Oncology Products

Stacy Shord, Deputy Division Director, FDA 

9:30 - 10:10 am 

Clinical consideration for Oncology dose optimization

Harald A.Weber, MD, Executive Medical Director, Seagen/Pfizer

10:10 - 10:20 am

Major Sponsor Presentation 

Allucent

10:20 - 10:40 am 

Break and Vendor Show 

 -

10:40 - 11:20 am

Oncology dose finding CDP for different molecule classes  

Patrick Williams, MD, Senior Medical Director, Genentech

11:20 - 11:50 am

Biostatistic consideration and adaptive designs for oncology dose finding

Hao Wang, PhD, Director, Clinical Data Science-Biostatistics, Gilead 

11:50am-12:30 pm

Clinical pharmacology considerations towards efficient oncology dose finding

Donghua Yin, PhD, VP, Pfizer

12:30 - 1:20 pm

Lunch 

 Sponsor (TBD)

1:20 - 2:00 pm

Patient reported outcome for oncology dose optimization

Peter C Trask, Ph.D., MPH Senior Director, Head of Oncology, Patient-Centered Outcomes Research, Genentech 

2:00 - 2:40 pm

Population PK, covariates characterization, and E-R for dose selection

Shelly Wang, Ph.D.

2:40 - 2:50 pm

Major Sponsor Presentation 

Olink Proteomics

2:50 - 3:15 pm

Break and Vendor Show 

-

3:15 - 3:50 pm

Oncology dose optimization - IQ consortium perspectives

Divya Samineni, PhD, Distinguished Scientist, Genentech

3:50 - 4:30 pm

Panel Discussion and Q&A

 All Speakers 

4:30 - 5:30 pm

Happy Hour

 Sponsor (TBD)


2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
┬ęPharmaceutical & BioScience Society, International; Last Modified: 4/23/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Submit a Text Ad